HIV Pathogenesis Research Unit

HIV Pathogenesis Research Unit is a specialized biomedical research entity based in South Africa, established in 2007. Operating as an academic research unit within a university environment, it focuses on translational and laboratory-driven investigations into HIV biology, treatment, and prevention. The unit plays a strategic role in addressing the regional and global burden of HIV through integrated molecular, pharmacological, and immunological research.

Its publications highlight strong expertise in antiretroviral drug resistance, particularly in HIV-1 subtype C, and in optimizing next-generation therapeutics such as lipid prodrugs of tenofovir and novel reverse transcriptase inhibitors. Advanced phenotypic assays, metabolomics, and pharmacokinetic analyses underpin efforts to improve drug stability, potency, and resistance profiling, directly informing treatment strategies.

The unit also advances HIV vaccine design through engineered Env trimers and bispecific antibodies aimed at eliciting broadly neutralizing responses. Complementary work in neurovirology, substance use disorders, and scientific education reflects interdisciplinary strength, reinforcing its position as a contributor to innovation in HIV therapeutics, prevention science, and capacity development.